Antisocial BehaviorNCT03035877
Multisystemic Therapy-Emerging Adults (MST-EA) for Substance Abuse
A study testing Multisystemic Therapy-Emerging Adults and Enhanced Treatment as Usual in people with Antisocial Behavior, run by Chestnut Health Systems at 4 sites in United States.
Trial summary
This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal activity. Read more about this study
- Who is it for?
- Ages 16 to 26 years
- Conditions the study is for
- Antisocial Behavior
- What is being tested?
- Multisystemic Therapy-Emerging Adults and Enhanced Treatment as Usual
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 183 participants
- Where
- 4 sitesUnited States
- Study dates
- 28 Aug 2017to 13 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 26 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age 16 to 26 years
- Recent arrest or release from jail/prison/detention (within the past 18 months but excluding arrest for parole/probation violations)
- Presence of alcohol or drug (AOD) abuse disorder and recent AOD use (within the past 90 days)
- Able to reside in a stable community setting (not currently homeless, not currently in-patient; can include individuals ready for discharge to the community)
Who cannot join
- Actively psychotic, suicidal, or homicidal
- Pervasive Development Disorders (PDD) or mental retardation
- Sex offending as the primary offense type
Trial locations and contacts
4 sites in 1 country.
United States4 sites
North American Family Institute
Hamden, Connecticut, 06518
North American Family Institute
Hartford, Connecticut, 06114
Youth Villages
Johnson City, Tennessee, 37601
North American Family Institute
New Haven, Connecticut, 06510
About this study
Official title: Treatment of Justice-Involved Emerging Adults With Substance Use Disorders
This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal activity. The study will also examine that effect on intermediate outcomes as follows: 1) reduced AOD use; 2) greater gainful activity (increased educational success, employment and housing stability; decreased antisocial peer involvement and relationship conflict); 3) and greater improvement in self-regulation (self-efficacy, goal directedness and responsibility taking). The intervention to be tested is Multisystemic Therapy-Emerging Adults (MST-EA). MST-EA is an adaptation of MST, a well-established, effective intervention for antisocial behavior in adolescents.
Read the detailed description
Prevalence of alcohol and other drug (AOD) abuse and criminal activity is highest during emerging adulthood compared to any other developmental period, and causes extraordinary costs to society. Emerging Adults (EAs; ages 17-26) with AOD abuse have greater incarceration rates than EAs without AOD abuse, and AOD-abusing offenders have significantly more recidivism, severe offending, and incarceration than other offenders. Such serious behavior interferes with successful transition into adulthood in areas such as school completion, employment and housing. Thus, there is a strong public health need for effective treatment to reduce AOD abuse and justice involvement in EAs. Surprisingly, there are no interventions with established efficacy to reduce criminal activity among EAs, with or without AOD abuse. Among younger adolescents, the comprehensive causes of antisocial behavior are addressed by effective interventions (e.g., Multisystemic Therapy [MST]; Treatment Foster Care Oregon [TFCO]), and the present investigative team has developed and evaluated a well-defined age-tailored intervention for EAs with criminal behavior. The developed intervention is an adaptation of MST and integrates a skills coaching component from TFCO, both well-established effective juvenile justice interventions. Initial MST-EA research focused on justice-involved young adults who had mental health problems, a high-risk subpopulation of offenders, but AOD abuse quickly became a primary problem the MST-EA team treated. As a single-source intervention, MST-EA targets the EA correlates of criminal activity and AOD abuse, including gainful EA activities (positive relationships, school, work, and housing) and reduced AOD abuse-in part by targeting the proximal mechanism of poor self-regulation. In a successfully completed community-based open trial, the safety, feasibility, and preliminary efficacy of the intervention were established.
The proposed study will evaluate the effectiveness of MST-EA for reducing justice involvement and AOD abuse. EAs (n = 240) with AOD abuse and justice involvement (recent arrests or release from justice facilities) will be randomized to receive MST-EA or Enhanced Treatment as Usual (E-TAU). Assessments will be completed at months 0, 2, 4, 6, 8, 12, and 16, with confirmation of outcome data using official records. Aims will be to evaluate the effect over time of MST-EA for reducing AOD abuse and criminal activity, as well as to evaluate the effect of MST-EA on the key proximal target of treatment (self-regulation) and intermediate outcomes of treatment (gainful activities). A final aim of the study will be to investigate if the direct effect of treatment on criminal activity is mediated by its effect on self-regulation, AOD abuse, and gainful activities. In this specific age group, there is a complete absence of AOD abuse and recidivism reduction treatments with demonstrated effectiveness. The ultimate effect of the proposed research would be decreased AOD abuse and justice involvement in a high-risk population, as well as improved outcomes that have significant societal impact (e.g., reduced homelessness and unemployment).
- Conditions
- Antisocial Behavior
- Being tested
- Multisystemic Therapy-Emerging Adults, Enhanced Treatment as Usual
- Keywords
- Antisocial Behavior, Alcohol Abuse, Drug Abuse, Young Adults
- Medical subject headings
- Antisocial Personality Disorder, Alcoholism, Substance-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multisystemic Therapy-Emerging AdultsBehavioural
Also called MST-EA
MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
Enhanced Treatment as UsualBehavioural
Also called E-TAU
With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
| Study group | Role | What they receive |
|---|---|---|
| Multisystemic Therapy-Emerging Adults | Experimental | This group will receive Multisystemic Therapy-Emerging Adults. Receives: Behavioral: Multisystemic Therapy-Emerging Adults |
| Enhanced Treatment as Usual | Active comparator | This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law. Receives: Behavioral: Enhanced Treatment as Usual |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in number and severity of criminal charges in official records in the 16 months pre-Baseline compared with the 16 months post-Baseline.
Changes from the 16 months pre-Baseline in offending as measured by the number and severity of criminal charges in official records compared to 16 months post-Baseline.
Measured: 16 months pre-Baseline compared with 16 months post-Baseline.
Changes from Baseline scores compared to 16 months post-Baseline Offending Behaviors (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Offending behaviors as measured using the Self-Report Offending Scale (self-reports).
Measured: Baseline to 16 months.
Secondary outcomes (12)
Changes from Baseline scores compared to 16 months post-Baseline Self-efficacy (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Self-efficacy as measured using the Self-Efficacy Scale (self-reports).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Goal Directedness (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Goal directedness measured using the Wills Self Control Measure (self-reports).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Responsibility Taking (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Responsibility taking measured using the Behavioral Indicators of Conscientiousness (self-reports).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Urine Drug/Alcohol Screens (measured at 0, 2, 4, 6, 8, 12 and 16 months).
The number of positive urine screens for tetrahydrocannabinol (THC), synthetic THC, amphetamines, methamphetamines, phencyclidine (PCP), opiates, benzodiazepines, cocaine, and specific metabolites of alcohol (Ethyl glucuronide, Ethyl sulfate).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Treatment Usage (measured at 0, 2, 4, 6, 8, 12 and 16 months).
The number of hospitalizations, emergency room visits and other treatments for alcohol or drug use as measured using the Time Line Follow Back (self-report) and from archival records.
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Substance Use and Problems (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Frequency of substance use and substance-related problems as measured by the Global Appraisal of Individual Needs (self-reports).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Antisocial Peers Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Antisocial peer involvement measured using the Peer Delinquency Scale (self-reports).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Interpersonal Competence (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Social conflict and social functioning as measured using the Interpersonal Competence Scale (self-reports).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Housing Stability (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Housing stability as measured using the Time Line Follow Back (self-reports) and from archival records.
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Relationship Closeness and Discord (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Relational closeness and relational discord as measured by the Network of Relationship Inventory (self-reports).
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline School/Employment Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Days in school or work (gainful activities) as measured using the Time Line Follow Back (self-reports) and from archival records.
Measured: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Mental Health Symptoms (measured at 0, 2, 4, 6, 8, 12 and 16 months).
The severity and number of mental health symptoms as measured using the Brief Symptom Inventory and the Posttraumatic Stress Disorder Checklist (self-reports).
Measured: Baseline to 16 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2017 (estimated)
- Study start28 Aug 2017
- Primary completion23 Mar 2023
- Study completion13 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Antisocial BehaviorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 183 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chestnut Health Systems
- Sponsor type
- University, hospital or other
- Collaborators
- University of Massachusetts, Worcester, Connecticut Department of Children and Families, North American Family Institute, Court Support Services Division, Youth Villages, Oregon Social Learning Center
- Responsible party
- Principal investigator, Ashli Sheidow, Chestnut Health Systems
- Investigators
- Ashli J Sheidow, Ph.D., Principal investigator, Chestnut Health SystemsMaryann Davis, Ph.D., Principal investigator, University of Massachusetts, Worcestor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03035877
- Sponsor's protocol ID
- 1R01DA041425-01
- Status last verified
- Apr 2026
- First submitted
- 26 Jan 2017
- Last updated
- 8 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treatment of Justice-Involved Emerging Adults With Substance Use Disorders
- ClinicalTrials.gov ID
- NCT03035877
- Acronym / sponsor ID
- 1R01DA041425-01
- Conditions
- Antisocial Behavior
- Keywords
- Antisocial Behavior, Alcohol Abuse, Drug Abuse, Young Adults
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 183 participants (actual)
- Lead sponsor
- Chestnut Health SystemsUniversity, hospital or other
- Collaborators
- University of Massachusetts, Worcester, Connecticut Department of Children and Families, North American Family Institute, Court Support Services Division, Youth Villages, Oregon Social Learning Center
- Study start
- 28 Aug 2017 (actual)
- Primary completion
- 23 Mar 2023 (actual)
- Study completion
- 13 Apr 2023 (actual)
- First posted
- 30 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study's purpose is to examine the effectiveness of a promising intervention for emerging adults (EAs) with alcohol and other drug (AOD) abuse and justice involvement in achieving the ultimate outcome of reduced criminal activity. The study will also examine that effect on intermediate outcomes as follows: 1) reduced AOD use; 2) greater gainful activity (increased educational success, employment and housing stability; decreased antisocial peer involvement and relationship conflict); 3) and greater improvement in self-regulation (self-efficacy, goal directedness and responsibility taking). The intervention to be tested is Multisystemic Therapy-Emerging Adults (MST-EA). MST-EA is an adaptation of MST, a well-established, effective intervention for antisocial behavior in adolescents.
Detailed description
Prevalence of alcohol and other drug (AOD) abuse and criminal activity is highest during emerging adulthood compared to any other developmental period, and causes extraordinary costs to society. Emerging Adults (EAs; ages 17-26) with AOD abuse have greater incarceration rates than EAs without AOD abuse, and AOD-abusing offenders have significantly more recidivism, severe offending, and incarceration than other offenders. Such serious behavior interferes with successful transition into adulthood in areas such as school completion, employment and housing. Thus, there is a strong public health need for effective treatment to reduce AOD abuse and justice involvement in EAs. Surprisingly, there are no interventions with established efficacy to reduce criminal activity among EAs, with or without AOD abuse. Among younger adolescents, the comprehensive causes of antisocial behavior are addressed by effective interventions (e.g., Multisystemic Therapy [MST]; Treatment Foster Care Oregon [TFCO]), and the present investigative team has developed and evaluated a well-defined age-tailored intervention for EAs with criminal behavior. The developed intervention is an adaptation of MST and integrates a skills coaching component from TFCO, both well-established effective juvenile justice interventions. Initial MST-EA research focused on justice-involved young adults who had mental health problems, a high-risk subpopulation of offenders, but AOD abuse quickly became a primary problem the MST-EA team treated. As a single-source intervention, MST-EA targets the EA correlates of criminal activity and AOD abuse, including gainful EA activities (positive relationships, school, work, and housing) and reduced AOD abuse-in part by targeting the proximal mechanism of poor self-regulation. In a successfully completed community-based open trial, the safety, feasibility, and preliminary efficacy of the intervention were established.
The proposed study will evaluate the effectiveness of MST-EA for reducing justice involvement and AOD abuse. EAs (n = 240) with AOD abuse and justice involvement (recent arrests or release from justice facilities) will be randomized to receive MST-EA or Enhanced Treatment as Usual (E-TAU). Assessments will be completed at months 0, 2, 4, 6, 8, 12, and 16, with confirmation of outcome data using official records. Aims will be to evaluate the effect over time of MST-EA for reducing AOD abuse and criminal activity, as well as to evaluate the effect of MST-EA on the key proximal target of treatment (self-regulation) and intermediate outcomes of treatment (gainful activities). A final aim of the study will be to investigate if the direct effect of treatment on criminal activity is mediated by its effect on self-regulation, AOD abuse, and gainful activities. In this specific age group, there is a complete absence of AOD abuse and recidivism reduction treatments with demonstrated effectiveness. The ultimate effect of the proposed research would be decreased AOD abuse and justice involvement in a high-risk population, as well as improved outcomes that have significant societal impact (e.g., reduced homelessness and unemployment).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Multisystemic Therapy-Emerging Adults | Experimental | Behavioral: Multisystemic Therapy-Emerging AdultsThis group will receive Multisystemic Therapy-Emerging Adults. |
| Enhanced Treatment as Usual | Active comparator | Behavioral: Enhanced Treatment as UsualThis group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law. |
Who may qualify
- Ages
- 16 to 26 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (4 listed)
- Age 16 to 26 years
- Recent arrest or release from jail/prison/detention (within the past 18 months but excluding arrest for parole/probation violations)
- Presence of alcohol or drug (AOD) abuse disorder and recent AOD use (within the past 90 days)
- Able to reside in a stable community setting (not currently homeless, not currently in-patient; can include individuals ready for discharge to the community)
Key exclusion criteria (3 listed)
- Actively psychotic, suicidal, or homicidal
- Pervasive Development Disorders (PDD) or mental retardation
- Sex offending as the primary offense type
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multisystemic Therapy-Emerging AdultsAlso: MST-EAMST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood. | Behavioural | Multisystemic Therapy-Emerging Adults |
| Enhanced Treatment as UsualAlso: E-TAUWith Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services. | Behavioural | Enhanced Treatment as Usual |
Primary outcome
Change in number and severity of criminal charges in official records in the 16 months pre-Baseline compared with the 16 months post-Baseline.
Time frame: 16 months pre-Baseline compared with 16 months post-Baseline.
Changes from the 16 months pre-Baseline in offending as measured by the number and severity of criminal charges in official records compared to 16 months post-Baseline.
Changes from Baseline scores compared to 16 months post-Baseline Offending Behaviors (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Offending behaviors as measured using the Self-Report Offending Scale (self-reports).
12 secondary outcomes
Changes from Baseline scores compared to 16 months post-Baseline Self-efficacy (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Goal Directedness (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Responsibility Taking (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Urine Drug/Alcohol Screens (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Treatment Usage (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Substance Use and Problems (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Antisocial Peers Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Interpersonal Competence (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Housing Stability (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Relationship Closeness and Discord (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline School/Employment Involvement (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Changes from Baseline scores compared to 16 months post-Baseline Mental Health Symptoms (measured at 0, 2, 4, 6, 8, 12 and 16 months).
Time frame: Baseline to 16 months.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Antisocial Behavior
Recruiting
Effects of Transcranial Magnetic Stimulation on Social Cognition, Cognitive Processing, and Functional Brain Architecture
Psychopathy
Recruiting
Virtual Reality (VR-GINSO) as an Complement to Intervention for Alcohol and Cannabis Use in Youth in Residential Care
Dual Diagnosis, Risk Youth
Recruiting
PSYCHOPATHY.COMP Program Among Male Prison Inmates With Psychopathy
Antisocial Personality Disorder (ASPD)
Recruiting
Listening Effort in Cochlear Implant Users
Auditory Perception; Abnormal, Hearing Loss, Sensorineural
Not yet recruiting
Evaluating the Feasibility and Effects of PULS
Anti Social Behavior
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ashli J Sheidow, Ph.D. principal investigator
Chestnut Health Systems
Maryann Davis, Ph.D. principal investigator
University of Massachusetts, Worcestor
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multisystemic Therapy-Emerging Adults and Enhanced Treatment as Usual in people with Antisocial Behavior, run by Chestnut Health Systems at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in number and severity of criminal charges in official records in the 16 months pre-Baseline compared with the 16 months post-Baseline. (time frame: 16 months pre-Baseline compared with 16 months post-Baseline.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.